Navco Pharmaceuticals Inc.
NAV.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 93.75% | 95.72% | 96.25% | -164.56% | 94.79% |
| Total Depreciation and Amortization | -100.00% | -97.50% | -93.83% | -93.90% | 210.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 100.79% | -99.48% | 7.69% | 139.38% | -111.57% |
| Change in Net Operating Assets | -100.86% | 108.23% | -93.96% | 187.59% | 154.46% |
| Cash from Operations | 50.81% | 92.66% | 99.36% | 94.38% | 98.17% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 19.35% | 27.54% | 88.51% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 525.00% | 20.00% | 163.89% | -97.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.33% | 128.77% | 96.23% | 99.23% | 98.78% |